The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

In a surprise double announcement Tuesday, Novo reduced sales guidance by 5%—attributing the change to slowed growth of its ...

Shares in Danish drugmaker Novo Nordisk were down nearly 20% in pre-market trading Tuesday morning after the company cuts its ...

Jared Holz, Mizuho health care equity strategist, joins 'Money Movers' to discuss Novo Nordisk sinking on guidance cut and ...

GLP-1 receptor agonists are an important drug class and have become widely popular due to their effectiveness in weight ...

Novo Nordisk faces a significant market value drop amid competition and leadership changes. Maziar Mike Doustdar has been ...

Partially a result, Novo Nordisk has steadily declined since last summer. Over the past year, NVO shares are down more than ...

Novo Nordisk's market value fell by $70 billion following a profit warning and the appointment of Maziar Mike Doustdar as the ...

NEW YORK -- U.S. stock indexes are tiptoeing around their record levels on Tuesday as an incredibly busy week for Wall Street ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Pharma giant Novo Nordisk A/S (NYSE:NVO) is plunging 21% to trade at a nearly three-year low of $54.27, after the company's ...

US stocks opened higher Tuesday amid strong corporate earnings, upcoming Fed rate decision, and anticipation around major ...